1227911-43-4

Basic information

• Product Name: (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide
• Synonyms: (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide
• CAS NO: 1227911-43-4
• Molecular Weight: 365.906
• Mol File: 1227911-43-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide(1227911-43-4)
• EPA Substance Registry System: (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide(1227911-43-4)

Safety Data

• Hazardous Substances Data: 1227911-43-4(Hazardous Substances Data)

Usage

General Description

The chemical compound "(3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide" is a complex organic molecule that consists of a cyclohexyl group, a pyrimidinyl group, a piperidinecarboxamide group, and a chlorine atom. It has a molecular formula that corresponds to C19H30ClN5O, and it is classified as a piperidinecarboxamide derivative. (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide may have pharmaceutical or biological applications due to its structural features. However, further research and testing would be necessary to determine its specific properties and potential uses.

Upstream product

• 1227911-36-5 (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-6-methyl-3-piperidinecarboxylic acid 
• 108-91-8 cyclohexylamine 
• 1227911-35-4 methyl (3S,6R)-6-methyl-3-piperidinecarboxylate L-tartaric acid salt 
• 1009376-87-7 methyl (3R*,6S*)-6-methylpiperidine-3-carboxylate 
• 10397-15-6 4,6-dichloro-N-methyl-2-pyrimidinamine 
• 5470-70-2 Methyl 6-methylnicotinate 

Downstream Products

• 1227911-44-5 (3S,6R)-1-[6-(4-cyano-3-fluorophenyl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide 
• 1227911-46-7 (3S,6R)-N-cyclohexyl-1-[6-(1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-6-methyl-3-piperidinecarboxamide 
• 1227911-53-6 (3S,6R)-N-cyclohexyl-6-methyl-1-[2-(methylamino)-6-(3-methyl-1H-indazol-6-yl)-4-pyrimidinyl]-3-piperidinecarboxamide 
• 1227911-55-8 (3S,6R)-1-[6-(4-cyano-3,5-difluorophenyl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide 
• 1227911-45-6 GKS2334470 

Relevant articles and documents

N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1

The present invention provides Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R1, R2, R3, and R6 are as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.